Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Knee Osteoarthritis: Stem Cells vs PRP or Hyaluronic Acid
Transcript
- 0:00SPEAKER_01: Welcome to the Sorona Cell Podcast.
- 0:02SPEAKER_01: Um I want you to imagine your knee joint is like a finely tuned mechanical engine.
- 0:08SPEAKER_00: Aaron Ross Powell A very, very squeaky engine for a lot of people.
- 0:10SPEAKER_01: Aaron Ross Powell Yeah, that is the unfortunate reality.
- 0:12SPEAKER_01: Now imagine the oil has completely run dry, the uh protective coating on the gears is wearing thin, and every single step you take just feels like metal grinding on metal.
- 0:23SPEAKER_00: Aaron Powell It is a painful visual, but a very accurate one.
- 0:26SPEAKER_01: Aaron Powell Today we are cutting through all the marketing hype to find out if modern medicine can actually fix that engine without replacing it entirely.
- 0:34SPEAKER_01: We are doing a deep dive into a really grounded, entirely evidence-based look at the non-surgical treatment options for neosteoarthritis that you hear about all the time, but um rarely get a straight answer on.
- 0:47SPEAKER_00: Aaron Powell And we are sifting through a massive stack of new data today, but I think we need to establish some firm ground rules before we even start pulling apart the numbers.
- 0:54SPEAKER_01: Oh, definitely.
- 0:55SPEAKER_00: Because we are talking about treatments that aim to delay surgery, but you, the listener, need to know up front none of these options physically replace a joint the way a titanium prosthesis does.
- 1:05SPEAKER_01: Yeah, you aren't getting a terminator leg out of an injection.
- 1:08SPEAKER_00: Precisely.
- 1:09SPEAKER_00: And none of them guarantee permanent relief.
- 1:11SPEAKER_00: And perhaps most importantly, based on the current evidence, none of these therapies support full cartilage regrowth.
- 1:17SPEAKER_01: So no turning back the clock to a brand new knee.
- 1:20SPEAKER_00: No.
- 1:21SPEAKER_00: The goal we are looking at in the data is pain relief and functional improvement, not perfect anatomy.
- 1:27SPEAKER_01: That is the perfect baseline to set.
- 1:29SPEAKER_01: The focus is absolutely on function and getting you back to your life.
- 1:33SPEAKER_01: But to understand the massive sets of numbers we are about to dive into, we first need to like understand the biology.
- 1:41SPEAKER_01: What are these treatments actually doing inside a knee?
- 1:44SPEAKER_00: Well, we have to look at the root problem first.
- 1:46SPEAKER_00: Knee osteoarthritis develops when the cartilage inside the joint simply wears down over time.
- 1:51SPEAKER_01: And the cartilage is that smooth, highly protective tissue at the ends of your bones.
- 1:56SPEAKER_00: Yes.
- 1:56SPEAKER_00: When that degrades, you lose your shock absorption, you get raw friction.
- 2:00SPEAKER_01: Which leads directly to the pain, the stiffness.
- 2:03SPEAKER_00: And swelling.
- 2:04SPEAKER_00: Which typically worsens the more you move.
- 2:07SPEAKER_00: The joint becomes fundamentally irritated, heavily inflamed, and just trapped in the cycle of degradation.
- 2:13SPEAKER_01: Aaron Powell So going back to our mechanical engine analogy, the gears are grinding.
- 2:17SPEAKER_01: To address this, you generally face three main injection options.
- 2:21SPEAKER_01: Um hyaluronic acid, which we'll call HA, platelet-rich plasma, or PRP, and stem cell therapy.
- 2:29SPEAKER_00: Those are the big three.
- 2:30SPEAKER_01: Let's break those down.
- 2:31SPEAKER_01: HA is essentially like injecting premium motor oil into that engine.
- 2:35SPEAKER_00: I like that analogy.
- 2:36SPEAKER_01: It just supplements the joint's natural lubricating fluid to reduce friction and you know cushion the movement directly.
- 2:42SPEAKER_00: But PRP takes a slightly different angle.
- 2:44SPEAKER_00: If HA is motor oil, PRP is more like a mechanics-targeted anti-rust spray.
- 2:50SPEAKER_01: Oh, I like that anti-rust spray.
- 2:52SPEAKER_00: Because you are concentrating your own platelets from a routine blood draw and injecting them into the joint.
- 2:57SPEAKER_00: Those platelets then release concentrated growth factors to actively calm the acute inflammation around those grinding gears.
- 3:04SPEAKER_01: Which brings us to the third option: stem cell therapy.
- 3:07SPEAKER_01: Specifically, mesenchymal stem cells, or MSCs.
- 3:13SPEAKER_01: This seems like a completely different approach from just, you know, lubricating the joint or spraying down the rust.
- 3:18SPEAKER_00: It is entirely different.
- 3:19SPEAKER_00: Instead of just adding fluid or short-term growth factors, mesenchymal stem cells act almost like microscopic pharmacy managers.
- 3:26SPEAKER_01: Pharmacy managers.
- 3:27SPEAKER_00: Yes, because when injected into the joint, they modulate the immune response, change the chemical makeup of the synovial fluid, and alter the joint's overall microenvironment.
- 3:37SPEAKER_00: They basically release specific signals that orchestrate a longer-term calming of inflammation.
- 3:43SPEAKER_01: Wait, are these stem cells actually rebuilding the engine or just telling the engine to stop overheating?
- 3:48SPEAKER_01: Because the way you hear it marketed, it sounds like they're patching up the gears.
- 3:52SPEAKER_00: This raises an important question, and it's one that researchers still heavily debate.
- 3:56SPEAKER_01: Really?
- 3:56SPEAKER_01: Still debating it.
- 3:57SPEAKER_00: Oh, absolutely.
- 3:58SPEAKER_00: How much of the clinical benefit from stem cells comes from actual tissue repair versus simple, highly potent control of inflammation?
- 4:07SPEAKER_00: The reality is, both mechanisms likely play some role in improving the joint's environment.
- 4:12SPEAKER_01: But the exact ratio is unknown.
- 4:15SPEAKER_00: It remains an open question in the literature.
- 4:17SPEAKER_00: We know the signaling changes the environment for the better, but it is not spontaneously regenerating a thick, brand new layer of pristine cartilage.
- 4:26SPEAKER_00: It's about changing the biological neighborhood so the joint can function without chronic pain.
- 4:31SPEAKER_01: Okay, so now that we know the theory behind these big three mechanisms, what happens when you put these options head to head in a massive statistical arena?
- 4:39SPEAKER_00: Well, the numbers get very interesting.
- 4:41SPEAKER_01: Our main source today is a 2024 network meta-analysis published in the journal Arthroscopy, and the sheer scale of this data is just incredible.
- 4:49SPEAKER_01: They pulled 48 distinct trials covering 9,338 knees.
- 4:54SPEAKER_00: That is a very robust data set.
- 4:56SPEAKER_01: And they directly compared corticosteroids, HA, PRP, and bone marrow aspirate concentrate, which is a cell-based option closely related to stem cell therapy.
- 5:05SPEAKER_00: To make sense of a data set that massive, the researchers used a statistical tool called a SUCRA score.
- 5:12SPEAKER_00: SUCRA stands for surface under the cumulative ranking curve.
- 5:17SPEAKER_01: Wait, SUCRA.
- 5:18SPEAKER_01: Surface under the cumulative ranking, so it's essentially just a probability score.
- 5:22SPEAKER_01: Like odds in Vegas for which treatment is most likely to win.
- 5:25SPEAKER_00: That is a very functional way to look at it.
- 5:27SPEAKER_00: It is a percentage that simply ranks the likelihood of a treatment being the absolute best option for improving pain and function across the entire pool of patients.
- 5:37SPEAKER_00: Aaron Powell Okay.
- 5:37SPEAKER_01: So a higher score means a higher probability of being the top performing treatment.
- 5:41SPEAKER_00: Aaron Powell Yes, among the specific options tested.
- 5:44SPEAKER_01: Aaron Powell Here is where it gets really interesting.
- 5:46SPEAKER_01: When the dust settled on those 9,000 plus knees, PRP actually scored the highest overall.
- 5:51SPEAKER_01: It did.
- 5:51SPEAKER_01: With a SECRA score of 91.54.
- 5:55SPEAKER_01: It was followed by the bone marrow cell-based option at 76.46, and then HA at 53.12.
- 6:02SPEAKER_00: And corticosteroids and placebos were dead last, scoring around 15, well behind every active treatment.
- 6:08SPEAKER_01: Yeah, the data clearly shows that steroid shots and placebos simply do not compete with the active biologic and lubricating options when you are looking at long-term joint function.
- 6:18SPEAKER_00: They fall far behind.
- 6:19SPEAKER_01: Okay, let's unpack this.
- 6:20SPEAKER_01: If you're a patient looking at this data, you might see that 91% score and think PRP is a magic bullet.
- 6:28SPEAKER_01: If PRP scored a 91.54 and the cell-based option scored a 76 picture, why do patients or clinics even bother exploring scem cells?
- 6:38SPEAKER_00: That is a very logical conclusion to draw at first glance.
- 6:41SPEAKER_01: Is PRP just the undisputed champion of knee osteoarthritis?
- 6:45SPEAKER_00: The answer to that lies hidden in a tiny column of the data that most people completely overlook when reading these flashy headlines, and that is the share of evidence.
- 6:53SPEAKER_01: The share of evidence.
- 6:54SPEAKER_00: If we connect this to the bigger picture, a SECRA score built on highly limited data carries high statistical uncertainty.
- 7:00SPEAKER_00: In this massive 2024 meta-analysis, HA made up nearly 41% of the pool of evidence.
- 7:06SPEAKER_01: Okay, so a huge chunk of the data was just HA.
- 7:09SPEAKER_00: Yes.
- 7:09SPEAKER_00: PRP made up 21.5%.
- 7:12SPEAKER_00: And the bone marrow cell-based option, that made up just 2.5% of the total data pool.
- 7:18SPEAKER_01: Oh, wow.
- 7:19SPEAKER_01: I mean, oh my goodness, 2.5%.
- 7:22SPEAKER_00: A tiny fraction.
- 7:23SPEAKER_01: So comparing the SECRE scores at face value is literally like looking at online restaurant reviews.
- 7:30SPEAKER_01: HA is the restaurant with 4.5 stars, but it has 4,000 reviews.
- 7:35SPEAKER_01: You know what you are getting.
- 7:36SPEAKER_01: The rating is incredibly stable.
- 7:38SPEAKER_00: It's predictable.
- 7:39SPEAKER_01: But the cell-based option is the trendy new place with 4.8 stars, but only 20 people have eaten there.
- 7:46SPEAKER_01: The score looks fantastic on paper, but you have to treat it with a bit more caution because the sample size is just so much smaller.
- 7:52SPEAKER_00: That is a very apt comparison.
- 7:54SPEAKER_00: One or two bad reviews could tank the whole average.
- 7:57SPEAKER_00: A high statistical ranking based on 2.5% of the evidence pool simply cannot be viewed with the same universal confidence as a slightly lower ranking built on dozens of trials and decades of history.
- 8:08SPEAKER_01: Yeah, that makes sense.
- 8:09SPEAKER_00: This gap in evidence volume is exactly why most major orthopedic guidelines still treat stem cell therapy as an emerging option rather than a standard first-line recommendation.
- 8:20SPEAKER_01: It's also incredibly important to note that this specific 2.5% slice of data only looked at bone marrow derived cells.
- 8:28SPEAKER_00: Yes, which is just one specific type.
- 8:31SPEAKER_01: The clinical reality is that the science is actively expanding far beyond just pulling cells from a patient's bone marrow.
- 8:38SPEAKER_01: For instance, at Cyrona Cells Clinic in Kuala Lumpur, they utilize umbilical cord-derived mesenchymal stem cells, known as WJMSCs.
- 8:47SPEAKER_00: We should probably clarify what WJMSEs are for anyone unfamiliar with.
- 8:51SPEAKER_00: The WJ stands for Wharton's Jelly.
- 8:53SPEAKER_00: This is the protective gelatinous tissue found inside an umbilical cord, and it is incredibly rich in mesenchymal stem cells.
- 8:59SPEAKER_01: So why use those instead of bone marrow?
- 9:01SPEAKER_00: Clinics utilize these because cells sourced from umbilical cords are biologically younger, highly proliferative, and often more robust than stem cells harvested from the bone marrow of an older patient who is already suffering from advanced osteoarthritis.
- 9:13SPEAKER_01: And that biological difference is a massive draw.
- 9:17SPEAKER_01: Cerona cell sees local patients, of course, but they also attract international visitors flying in from Australia and the Middle East, who are specifically seeking out these evolving Wharton's jelly therapies.
- 9:29SPEAKER_00: It is a rapidly growing field.
- 9:31SPEAKER_01: The field's moving so fast, and the massive meta-analyses are always playing catch-up to the actual clinical applications happening on the ground.
- 9:38SPEAKER_00: And because that massive meta-analysis had such a small pool of cell-based data and primarily focused on older bone marrow techniques, researchers have had to run totally separate targeted studies just to see how stem cells fare against the old reliable standard, HA.
- 9:54SPEAKER_01: So let's look at one of those targeted studies in our stack.
- 9:57SPEAKER_01: This one focused specifically on mesenchymal stem cells, pooling 15 trials and 585 patients.
- 10:03SPEAKER_00: And it compared bone marrow-drive stem cells directly against HA.
- 10:07SPEAKER_01: The headline finding here was that the stem cells showed a significant improvement in pain scales, specifically VAS scores, compared directly to HA.
- 10:16SPEAKER_00: Let's quickly define VAS for anyone not deep in medical literature.
- 10:20SPEAKER_00: VAS is the visual analog scale.
- 10:23SPEAKER_00: The smiley face chart.
- 10:24SPEAKER_00: Essentially, yes.
- 10:25SPEAKER_00: It's basically a formal version of that one to ten pain scale you see in the doctor's office with the little smiley and fowny faces.
- 10:33SPEAKER_00: The data showed that stem cell injections brought those pain numbers down significantly more than HA did.
- 10:39SPEAKER_01: But there's always a butt.
- 10:41SPEAKER_00: We have to immediately bring in the caveat, which is the side effect profile.
- 10:44SPEAKER_01: There it is, the catch.
- 10:45SPEAKER_00: In that same research, the stem cell injections had more reported adverse reactions than the traditional HA therapy, even though the overall pain outcomes were favorable.
- 10:54SPEAKER_01: Aaron Powell What kind of reactions are we talking about?
- 10:56SPEAKER_00: Now these reactions were generally mild and short-lived, typically involving temporary swelling, stiffness, or soreness at the injection site for a few days, but they were statistically more frequent.
- 11:06SPEAKER_01: Aaron Powell So as a patient, how do you navigate that?
- 11:09SPEAKER_01: You might get statistically better long-term pain relief, but you are rolling the dice on a sore, swollen knee for a few days afterwards.
- 11:17SPEAKER_00: This is the classic medical trade-off.
- 11:19SPEAKER_00: A treatment can absolutely outperform another in pain relief while still carrying a different, sometimes higher, side effect profile.
- 11:26SPEAKER_01: So you have to weigh the two.
- 11:27SPEAKER_00: The headline pain scores are only half the conversation.
- 11:30SPEAKER_00: You have to factor in the recovery from the injection itself.
- 11:34SPEAKER_00: This trade-off is another reason why professional bodies often list PRP and HA as established or reasonable options to discuss first while maintaining more cautious language around stem cells until the broader evidence base grows.
- 11:47SPEAKER_01: Data and side effects are one thing, but how do these options differ when you look at your wallet and your calendar?
- 11:53SPEAKER_01: Because let's be real, the practical realities of choosing a treatment are often what actually dictate patient care.
- 11:59SPEAKER_00: Finances and logistics are huge factors.
- 12:01SPEAKER_01: Let's look at those logistics.
- 12:03SPEAKER_01: H8 is usually the cheapest option.
- 12:05SPEAKER_01: It has a massive manufacturing history.
- 12:07SPEAKER_01: It is widely covered by insurance and many healthcare systems, but it often requires a short series of weekly clinic visits.
- 12:14SPEAKER_00: Yes, multiple trips to the doctor.
- 12:16SPEAKER_00: PRP sits in the middle tier for cost.
- 12:18SPEAKER_00: It requires drawing and processing your own blood in a centrifuge, and usually involves just a single session or a few spread out over time.
- 12:26SPEAKER_01: And then stem cells.
- 12:27SPEAKER_00: Stem cell therapy, on the other hand, is often classified as experimental by insurance companies.
- 12:32SPEAKER_00: That means significantly higher out-of-pocket cost for the patient.
- 12:36SPEAKER_01: Though it also typically involves just one or a few targeted sessions, right?
- 12:40SPEAKER_01: I mean it's not a weekly thing, usually.
- 12:42SPEAKER_00: Correct.
- 12:43SPEAKER_00: Then we have to weigh those logistics against the safety profiles.
- 12:47SPEAKER_00: HA has decades of safety data.
- 12:50SPEAKER_00: It is a highly known entity in the medical world.
- 12:52SPEAKER_00: PRP is also considered very safe because it uses your own autologous blood.
- 12:57SPEAKER_00: You are not introducing a foreign substance into your body.
- 13:00SPEAKER_01: It's just your own platelets.
- 13:02SPEAKER_00: Yes.
- 13:03SPEAKER_00: Stem cells, as we noted, have those mild temporary reactions.
- 13:07SPEAKER_00: But the crucial point that applies across the entire field, not just to one specific treatment or clinic, is that none of these three options have meaningful long-term safety data beyond a few years.
- 13:18SPEAKER_01: Wait, really?
- 13:19SPEAKER_01: None of them.
- 13:19SPEAKER_00: We know exactly how patients fare at the one-year or two-year mark, but the decade-long safety profiles for the newer biologic therapies simply do not exist yet because the science hasn't been around long enough.
- 13:30SPEAKER_01: So what does this all mean?
- 13:31SPEAKER_01: If HA and PRP are cheaper, have more long-term safety data, are more widely recommended by guidelines, and PRP actually topped that massive SERA probability score who is actually flying to Kuala Lumpur or driving to their local clinic for stem cell therapy.
- 13:48SPEAKER_00: It comes down to the clinical reality of sequencing.
- 13:51SPEAKER_01: Sequencing.
- 13:51SPEAKER_00: No single injection works best for every patient.
- 13:54SPEAKER_00: And very rarely do patients jump straight to the most advanced, expensive option on day one.
- 14:00SPEAKER_00: Patients usually start with HA or PRP.
- 14:02SPEAKER_01: Because they're the standard first line.
- 14:04SPEAKER_00: Those are the logical first steps given the massive evidence base and the lower cost.
- 14:08SPEAKER_00: Stem cells typically enter the serious conversation after HA or PRP, only provide short-lived relief or no relief at all.
- 14:15SPEAKER_01: Okay.
- 14:16SPEAKER_01: So the patient has done the physical therapy, it hasn't resolved the ongoing pain, and they are looking at their MRI knowing that a full invasive joint replacement surgery feels premature.
- 14:25SPEAKER_00: Or they simply want to explore every possible option to delay that massive surgery.
- 14:30SPEAKER_01: They're exhausting their non-surgical options.
- 14:32SPEAKER_00: A physician typically reviews the imaging, the prior treatments tried, and the overall joint condition before recommending any specific option.
- 14:41SPEAKER_00: Weight, activity level, and disease severity all factor heavily into that decision.
- 14:47SPEAKER_00: All this data we have discussed today is just a map.
- 14:50SPEAKER_00: You still need a medical guide to walk the path.
- 14:52SPEAKER_01: Because the stats don't know the individual patient.
- 14:56SPEAKER_00: Rankings describe averages across large groups, but they are not guarantees for any one individual.
- 15:02SPEAKER_01: It's a clear progression.
- 15:03SPEAKER_01: Sorona cell actually has a Polish guide on this exact sequencing detailing how to utilize stem cell therapies specifically for joint pain after PRP and physio has stopped working.
- 15:13SPEAKER_01: The decision isn't happening in a vacuum, it is happening on a timeline of a patient's lived experience with osteoarthritis.
- 15:19SPEAKER_00: What's fascinating here is how these advancing therapies challenge our traditional medical goals.
- 15:24SPEAKER_01: How do you mean?
- 15:26SPEAKER_00: Well, if none of these advanced treatments actually regrow cartilage, but they can significantly delay surgery and restore daily function by changing the joint's inflammatory environment, maybe we need to rethink our definition of what a healed joint actually is.
- 15:38SPEAKER_01: Oh, that's deep.
- 15:39SPEAKER_00: Is the ultimate goal perfect, pristine anatomy on an X-ray, or is it simply a life without pain?
- 15:46SPEAKER_01: That is a phenomenal question to leave on.
- 15:49SPEAKER_01: As the science continues to evolve, our definitions of success might need to evolve right along with it.
- 15:55SPEAKER_01: No amount of ranking data, SUCRA scores, or meta-analyses replaces a doctor looking at your specific imaging and your specific medical history.
- 16:05SPEAKER_00: Very true.
- 16:06SPEAKER_01: And we have to reiterate the importance of standard care.
- 16:09SPEAKER_01: Lifestyle factors dictate outcomes regardless of what you inject into your joint.
- 16:13SPEAKER_01: Weight management and appropriate exercise are not afterthoughts.
- 16:16SPEAKER_01: They are mandatory baseline care.
- 16:18SPEAKER_00: They absolutely are.
- 16:20SPEAKER_01: Stay curious.
- 16:20SPEAKER_01: Keep asking hard questions about the data and the evidence shared behind the headlines.
- 16:24SPEAKER_01: If you are dealing with these joint issues, make sure you have your physician thoroughly review your imaging to discuss realistic options for your specific case.